
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This study is looking at AZD6738 for solid cancers that have spread to another part of the body. A is any cancer apart from cancers of the blood such as leukaemia and lymphoma.
There are 2 parts to this study. This summary is about the dose escalation study. We have another summary about the dose expansion study.
AZD6738 is a new drug. It works by stopping a protein called ATR. A change () in the ATR protein causes some cancers to grow and multiply.
Researchers think AZD6738 combined with other anti cancer drugs might work well to stop cancer growing.
But first they need to find the best dose of AZD6738 to give by itself and in combination with the other drugs.
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
You may be able to join the study if you are in one of the following situations.
You have that has spread to another part of the body and there is no further
.
Or
You have non small cell cancer (NSCLC) and:
Or
You have a head and neck cancer that is a and:
And all of the following apply, you:
You cannot join this study if any of these apply.
Cancer related
Medical conditions
Other
There are different parts to the study and you might not be able to join a certain part if any of the following also apply. You:
There are separate parts to this study. Which part you are in will depend on your cancer type and when you join.
This is a phase 1 study. The study team need about 156 people in total to take part.
The first few people to take part will have a low dose of AZD6738. If they don’t have any bad side effects the next few will have a higher dose. And so on until the highest safe dose is found. This is a dose escalation study.
After this they want to find the best dose of AZD6738 to give with:
They do this the same way as above. Which drug you have depends on your type of cancer.
AZD6738 is a tablet. You take it on an empty stomach. You can’t eat or drink anything apart from water for 2 hours before, or an hour after, taking your tablets. Your doctor will tell you how many to take.
You have carboplatin as a drip into a vein every 3 or 4 weeks. You have 6 treatments.
Olaparib is a tablet. Your doctor will tell you when to take them and how many.
You continue having olaparib and AZD6738 for as long as it is helping you and the side effects aren’t too bad.
You have durvalumab as a drip into a vein every 6 weeks. You continue having durvalumab and AZD6738 for as long as it is helping you and the side effects aren’t too bad.
Samples
The researchers will ask for samples of tissue ().These might be samples you have had taken previously. Or they may ask you to have a biopsy done while you are in the study. Not everyone will need to have additional biopsies. It will depend on which part of the study you join. The researchers will explain more.
You have some additional blood tests as part of this study. These are to measure specific substances in the blood ().
You will be asked if you’re willing to have an extra blood test. This is for genetic research. You do not have to give this sample if you don’t want to. You can still take part in the main study.
The researchers use all these samples to find out more about cancer and how AZD6738 works.
You see the doctor and have some tests before taking part. These tests include:
During treatment you see the doctor regularly and have the same tests. How often you have them depends on which treatment you are having.
A month after finishing treatment you see the doctor and have the same tests.
You then see the doctor every 6 to 8 weeks until your cancer starts to grow again.
AZD6738 is a new drug. This is the first time it is being used in humans and there may be side effects we don’t know about yet. Side effects of AZD6738 might include:
You are monitored very closely while taking AZD6738. Tell your doctor or nurse if your general health changes while taking AZD6738.
Durvalumab is a new drug and again there may be side effects we don’t know about yet. The most common side effects include:
We have information on the side effects of:
Your doctor will talk to you about the side effects before you agree to take part.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Matthew Krebs
AstraZeneca
Experimental Cancer Medicine Centre (ECMC)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.